Pharmaceutical

Influenza (quadrivalent) vaccine by Pfizer for Influenzavirus B Infections: Likelihood of Approval

Influenza (quadrivalent) vaccine is under clinical development by Pfizer and currently in Phase III for Influenzavirus B Infections.

May 17, 2024 - 04:00
Influenza (quadrivalent) vaccine is under clinical development by Pfizer and currently in Phase III for Influenzavirus B Infections.
Read the original article

Tags:

Previous Article

Opzelura by Incyte for Graft Versus Host Disease (GVHD): Likelihood of Approval

Next Article

Influenza (quadrivalent) vaccine by Pfizer for Influenzavirus A Infections: Like...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Regeneron is interested in obesity treatments that combat muscle loss

Regeneron is interested in obesity treatments that comb...

Feb 5, 2024

Bavarian Nordic wins positive CHMP opinion to amend Imvanex approval

Bavarian Nordic wins positive CHMP opinion to amend Imv...

Jul 28, 2024

STAT+: Physician buy-in will make or break VC firm General Catalyst’s bold hospital deal

STAT+: Physician buy-in will make or break VC firm Gene...

Jan 22, 2024